ライフサイエンスコーパス: depressive symptom

1 connectivity was positively correlated with depressive symptoms.

2 , and baseline reading ability, anxiety, and depressive symptoms.

3 6Ser (P-value=7.1 x 10(-03), beta=2.55) with depressive symptoms.

4 and physical activity, while controlling for depressive symptoms.

5 usting for concurrent changes in severity of depressive symptoms.

6 h was associated with higher QOL and reduced depressive symptoms.

7 Rotterdam study (RS), who were assessed for depressive symptoms.

8 ression Inventory II was completed to assess depressive symptoms.

9 ary outcomes were problem-solving skills and depressive symptoms.

10 e separate clinical trials of psilocybin for depressive symptoms.

11 hildren exposed to higher maternal perinatal depressive symptoms.

12 CIT optimizes the treatment of co-occurring depressive symptoms.

13 ccounted for intervention effects on QOL and depressive symptoms.

14 abetic macular edema was not associated with depressive symptoms.

15 nd indirect exposures to Occupy Central with depressive symptoms.

16 ty and/or depressive disorders and improving depressive symptoms.

17 more accurately than one-time assessment of depressive symptoms.

18 t not DME, was independently associated with depressive symptoms.

19 7%-44.4%) of the total explained variance of depressive symptoms.

20 e associated with the onset of at least some depressive symptoms.

21 tter QOL and decreased pain, disability, and depressive symptoms.

22 ed statistically significant improvements in depressive symptoms.

23 scores indicative of clinically significant depressive symptoms.

24 was independently related to one's partner's depressive symptoms.

25 ls (CIs) were calculated for moderate/severe depressive symptoms.

26 pression and especially inflammation-related depressive symptoms.

27 creased amygdala CBF correlated with reduced depressive symptoms.

28 ess to distress to disorder, for classifying depressive symptoms.

29 was used as a cutoff to indicate significant depressive symptoms.

30 and for psychosocial functioning, including depressive symptoms.

31 ncreased prevalence of suicidal ideation and depressive symptoms.

32 sion, and 32 patients (20.8%) had borderline depressive symptoms.

33 or depression and the later manifestation of depressive symptoms.

34 Self-guided iCBT is effective in treating depressive symptoms.

35 o for 12 weeks did not significantly improve depressive symptoms.

36 s, socioeconomic status, social support, and depressive symptoms (0.83; 95% CI, 0.71-0.97; P = .02).

37 0.51-1.07), chronic stress=1.25 (0.90-1.72), depressive symptoms=1.19 (0.76-1.85), and hostility=0.95

38 Depressive symptoms (17%) and post-traumatic stress diso

39 , history of falling or gait impairment, and depressive symptoms (2-item Patient Health Questionnaire

40 ed 2.9% of the estimated genetic variance of depressive symptoms (22%) in ERF.

41 tudies; 8%-74% decrease) and the severity of depressive symptoms (6 studies; 40%-70% decrease).

42 d a significant earlier reduction (24.9%) in depressive symptoms (95% CI, 13.9 to 35.9; t337 = 4.46;

43 ng nonwhite individuals, lifetime stress and depressive symptoms accounted for most of the effect (WQ

44 ssion showed that higher lifetime stress and depressive symptoms accounted for most of the effect on

45 e functional dysconnectivity and severity of depressive symptoms across diagnostic categories using a

46 S was unrelated to behavior, self-esteem and depressive symptoms adjusted for infant characteristics

47 estimate of the prevalence of depression or depressive symptoms among medical students was 27.2% and

48 April 2011 and March 2013, the prevalence of depressive symptoms among private renters receiving the

49 80 individuals (15.4%) screened positive for depressive symptoms and 118 persons (22.7%) screened pos

50 r prominent risk factors, including baseline depressive symptoms and adolescent and parental lifetime

51 n, and household income), and psychological (depressive symptoms and cognitive capacity) risk factors

52 tal Anxiety and Depression Scale anxiety and depressive symptoms and Global Mood Scale negative and p

53 ed greatest mortality for women who reported depressive symptoms and had not initiated ART.

54 We characterized the relationship between depressive symptoms and hippocampal microglial activatio

55 ence did not mediate the association between depressive symptoms and HRQOL.

56 to positive memories significantly decreased depressive symptoms and increased the percent of specifi

57 rge clinicians and policy makers to consider depressive symptoms and low socioeconomic status as syne

58 within-person association was found between depressive symptoms and LTL at each year (B=-0.8; P=0.54

59 Associations between maternal depressive symptoms and magnetic resonance imaging measu

60 Our results support a continuum between depressive symptoms and major depressive disorder.

61 y contribute to the emergence of anxiety and depressive symptoms and may play a critical role in the

62 gn was used, on the basis of the presence of depressive symptoms and metabolic dysregulation (obesity

63 CI): 4.86-9.01), compared with those without depressive symptoms and metabolic dysregulation (referen

64 Participants with both depressive symptoms and metabolic dysregulation had the

65 -2.17) suggested that the combined effect of depressive symptoms and metabolic dysregulation was grea

66 tudy was to evaluate the interaction between depressive symptoms and metabolic dysregulations as risk

67 found no evidence for an association between depressive symptoms and mtDNAcn.

68 The phenotypic associations between atypical depressive symptoms and obesity-related traits may arise

69 Lurasidone significantly improved depressive symptoms and overall illness severity, assess

70 ts and antidopaminergics can improve bipolar depressive symptoms and perhaps actions at other recepto

71 a collaborative care intervention can reduce depressive symptoms and prevent more severe depression i

72 Depressive symptoms and stronger social connectedness we

73 erobic exercise is being proposed to improve depressive symptoms and substance abuse outcomes.

74 d antibodies against cytokines) may decrease depressive symptoms and thus represent an attractive alt

75 Identifying fathers most at risk of depressive symptoms and when best to target intervention

76 he primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations

77 ctive well-being, 2 variants associated with depressive symptoms, and 11 variants associated with neu

78 There was evidence that social integration, depressive symptoms, and alcohol consumption partially m

79 herapy improved QoL, mood state, anxiety and depressive symptoms, and daytime sleepiness compared wit

80 rer on all measures of intelligence, anxiety/depressive symptoms, and executive function (differences

81 habilitation, management of malnutrition and depressive symptoms, and fall prevention, improved self-

82 ths and added management of malnutrition and depressive symptoms, and fall prevention.

83 usting for relevant baseline health factors, depressive symptoms, and health behaviors (fully adjuste

84 ships between hippocampal neuroinflammation, depressive symptoms, and hippocampal functional connecti

85 Anger, anxiety, chronic stress, depressive symptoms, and hostility were measured using v

86 he psychological variables perceived stress, depressive symptoms, and neuroticism; using formal genet

87 % CI, 23.9%-83.2%) of the unique variance in depressive symptoms, and severe NPDR or PDR contributed

88 (SES); PM2.5 was positively associated with depressive symptoms, and significantly for 30-day moving

89 ariates, lifestyle factors, medical history, depressive symptoms, and social integration measures.

90 also increasingly reported anxiety symptoms, depressive symptoms, and use of laxatives throughout stu

91 less positive affect, but no differences in depressive symptoms, angina, or Type D personality when

92 es over 28 years, these results suggest that depressive symptoms are a prodromal feature of dementia

93 Depressive symptoms are common in multiple psychiatric d

94 nd investigate its role in stress levels and depressive symptoms, as well as in HRQOL and disease act

95 The primary outcome was self-report of depressive symptoms assessed by BDI-II score (range 0-63

96 Inventory score at 11 years (n = 6937) and depressive symptoms assessed from self-reported Patient

97 Depressive symptoms assessed on 9 occasions between 1985

98 r Universities Arthritis Index (WOMAC)]; and depressive symptoms [assessed with the Center for Epidem

99 red between groups, and cognition during the depressive symptom assessment period (baseline to year 5

100 8 black and white older adults with repeated depressive symptom assessments from baseline to year 5 w

101 eward-related VS activity may buffer against depressive symptoms associated with poor sleep.

102 were seen in objective physical function or depressive symptoms at 12 months in any of the intervent

103 The primary outcome was improvement in depressive symptoms at 12 weeks with the Quick Inventory

104 ng were associated with higher QOL and lower depressive symptoms at 24 weeks.

105 ically significant reductions in anxiety and depressive symptoms at 3 months.

106 in a statistically significant difference in depressive symptoms at 4-month follow-up, of uncertain c

107 e intervention was associated with decreased depressive symptoms at 6 months (P = 0.017), but there w

108 tors may be associated with decreased family depressive symptoms at 6 months, but we found no signifi

109 e-Depression subscale prevalence (95% CI) of depressive symptoms at a threshold score greater than or

110 , comorbidity score, cognitive function, and depressive symptoms at baseline were controlled.

111 as associated with dementia incidence, while depressive symptoms at individual time points were not.

112 formance but did not affect the frequency of depressive symptoms at least in the short range.

113 However, most studies have measured depressive symptoms at only one time point, and older ad

114 nts for at least 6 weeks and had substantial depressive symptoms (Beck Depression Inventory [BDI-II]

115 In the 9 longitudinal studies that assessed depressive symptoms before and during medical school (n

116 emographic, health/medical risk factors, and depressive symptoms, being socially integrated was signi

117 rence to treatment was associated with lower depressive symptoms (beta = -0.19; P = .001) and greater

118 roticism (beta = 1.01; 95% CI, 0.50-1.52) or depressive symptoms (beta = 0.87; 95% CI, 0.32-1.42) and

119 economic factors, health-related behaviours, depressive symptoms, biological factors, cognitive perfo

120 on and some benefit with respect to mood and depressive symptoms but no benefit with respect to vital

121 ence suggests that NMDAR antagonists relieve depressive symptoms by forming new synapses resulting in

122 lyses reflected improvements in negative and depressive symptoms by ITI-007 60 mg.

123 tertiary Lyme center, to investigate whether depressive symptoms can be used in clinical practice to

124 fective interventions targeting preoperative depressive symptoms can reduce postoperative risk in thi

125 This suggests that depressive symptoms cannot be used to discriminate for L

126 r to dementia diagnosis to determine whether depressive symptoms carry risk for dementia.

127 e used to identify clusters of symptoms in a depressive symptom checklist.

128 of self-guided iCBT in treating adults with depressive symptoms compared with controls and evaluate

129 that in those with dementia, differences in depressive symptoms compared with those without dementia

130 The prevalence of suprathreshold depressive symptoms (compatible with Hospital Anxiety an

131 lack of correlation between PDE4 binding and depressive symptoms could reflect the heterogeneity of t

132 Depressive symptoms decreased at least partially with ti

133 However, depressive symptoms decreased significantly more when CI

134 e association between sleep disturbances and depressive symptoms decreased.

135 cores (P = 0.126), physical performance, and depressive symptoms did not differ between groups.

136 imaging neurofeedback (rtfMRI-nf) training, depressive symptoms diminish.

137 s, study-defined inefficacies, cognitive and depressive symptoms, discontinuation of treatment becaus

138 sought to assess over time the prevalence of depressive symptoms during and after the Occupy Central

139 ping T2DM if they experienced high levels of depressive symptoms during both adolescence and adulthoo

140 ell-being polygenic scores experienced fewer depressive symptoms during follow-up.

141 The mean (SD) number of depressive symptom elevations among the PSE participants

142 SE intervention is efficacious in preventing depressive symptom episodes and performs optimally among

143 of older adults have clinically significant depressive symptoms, even in the absence of major depres

144 g polygenic score buffered against increased depressive symptoms following a spouse's death.

145 es (N=1,647) experienced a sharp increase in depressive symptoms following the death and returned tow

146 her polygenic scores were less vulnerable to depressive symptoms following the death of their spouse

147 5 was significantly associated with incident depressive symptoms for all exposure windows examined, b

148 ks 6 and 12 had a 15% greater improvement in depressive symptoms from baseline over the course of tre

149 Those with chronic/recurring depressive symptoms (>/=2 of 3 occasions) in the early s

150 s low levels of anxiety, chronic stress, and depressive symptoms had 2-fold higher risk of incident H

151 Individuals with depressive symptoms had elevated risk of mortality on th

152 le adjustment for age, socioeconomic status, depressive symptoms, health-related behaviours, and chro

153 ion of whole-body hyperthermia (WBH) reduced depressive symptoms; however, the lack of a placebo cont

154 vALIC resulted in a significant decrease of depressive symptoms in 10 of 25 patients and was tolerat

155 Those reporting depressive symptoms in 1985 (mean follow-up, 27 years) d

156 However, those with depressive symptoms in 2003 (mean follow-up, 11 years) h

157 mined the association between high levels of depressive symptoms in adolescence and T2DM in adulthood

158 to longitudinally assess the extent to which depressive symptoms in adolescents change after contact

159 common in patients with dementia but whether depressive symptoms in adulthood increases the risk for

160 overlap with genes which may be involved in depressive symptoms in an aging non-psychiatric human po

161 ant single nucleotide polymorphism (SNP) for depressive symptoms in ANK3 from our GWAS has a relation

162 echanism underlying biased memory recall and depressive symptoms in currently depressed adults and tw

163 primary outcome was "target symptoms" (e.g., depressive symptoms in depressive disorders).

164 rare exonic variants influence the burden of depressive symptoms in families.

165 ION: Our results show an association between depressive symptoms in fathers and depressive symptoms i

166 span in individuals with the risk allele for depressive symptoms in men (odds ratio (OR) 1.41, P=0.03

167 ctively recorded ELS predict more pronounced depressive symptoms in midlife.

168 and objectively recorded ELS in relation to depressive symptoms in midlife.

169 re is little evidence to guide management of depressive symptoms in older people.

170 Neuropsychiatric symptoms, depressive symptoms in particular, are common in patient

171 of supraphysiologic thyroid hormone improves depressive symptoms in patients with bipolar disorder by

172 e whether treatment with sertraline improves depressive symptoms in patients with CKD and MDD.

173 ession was associated with the occurrence of depressive symptoms in patients with glaucoma.

174 The odds ratio for moderate/severe depressive symptoms in patients with LB and positive ser

175 ilar effect and significant association with depressive symptoms in samples from the independent popu

176 erages and added sugars has been linked with depressive symptoms in several populations.

177 study objective was to assess prevalence of depressive symptoms in subgroups of patients referred to

178 ed 0.9% of sex- and age-adjusted variance of depressive symptoms in the discovery study, which is tra

179 Depressive symptoms in the early phase of the study corr

180 96Ser variant of LIPG in the pathogenesis of depressive symptoms in the general population.

181 nonymous variation in the gene NKPD1 affects depressive symptoms in the general population.

182 19-40 years with information about onset of depressive symptoms in the perinatal period and complete

183 te rental sector increased the prevalence of depressive symptoms in the United Kingdom.

184 n between depressive symptoms in fathers and depressive symptoms in their adolescent offspring.

185 kable effects in reducing pain, anxiety, and depressive symptoms in these patients.

186 association between paternal and adolescent depressive symptoms in two large population-based cohort

187 d postpartum women for depression may reduce depressive symptoms in women with depression and reduce

188 on mortality, as well as a harmful effect of depressive symptoms, in a cohort of HIV-infected women.

189 findings do not support the hypothesis that depressive symptoms increase the risk for dementia.

190 s experienced a smaller decrease in HRQOL as depressive symptoms increased.

191 rect effect, 1.27; 95% CI, 0.33 to 2.86) and depressive symptoms (indirect effect, -0.39; 95% CI, -0.

192 ow-up), for whom we were able to incorporate depressive symptoms into the outcome definition, higher

193 opolitical conflict was associated with more depressive symptoms (IRR = 1.05, 95% CI: 1.01, 1.09).

194 After adjustment for physical health status, depressive symptoms, marital status, level of education,

195 Separate depressive symptoms may be encoded by differential chang

196 Since patients with anxiety and depressive symptoms may have a higher intrinsic risk of

197 Individuals' trajectory of depressive symptoms may inform dementia risk more accura

198 Some depressive symptoms may result from aberrant valuations,

199 Adolescents self-reported depressive symptoms (Mood and Feelings Questionnaire [MF

200 beginning antidepressant therapy to improve depressive symptoms more quickly, mitigate concomitant a

201 otypes: subjective well-being (n = 298,420), depressive symptoms (n = 161,460), and neuroticism (n =

202 15482041 showed significant association with depressive symptoms (N=2393, betaT-allele=2.33, P-value=

203 acting antidepressants such that relief from depressive symptoms occurs within hours of a single inje

204 daptive changes that may provide relief from depressive symptoms, often referred to as the self-medic

205 her dose was superior to placebo in reducing depressive symptoms on the primary end point or any seco

206 antiretroviral therapy (ART) initiation and depressive symptoms on time to death using a joint margi

207 (OR 1.95, 95% CI 1.63-2.36, p < 0.001), and depressive symptoms (OR 1.30, 95% CI 1.12-1.52, p < 0.00

208 for studies on the prevalence of depression, depressive symptoms, or suicidal ideation in medical stu

209 Quality of life and psychotic and depressive symptom outcomes were found to be better with

210 To characterize the trajectory of depressive symptoms over 28 years prior to dementia diag

211 older adults may show different patterns of depressive symptoms over time.

212 ion, which was significantly associated with depressive symptoms (P-value=5.2 x 10(-08), beta=7.2).

213 City Cardiomyopathy Questionnaire (P=0.009), depressive symptoms (P=0.027), and the 6-minute walk tes

214 KYNA/QUIN ratio reported significantly worse depressive symptoms (p=0.04), and a trend toward worse a

215 ion (Short Physical Performance Battery) and depressive symptoms (Patient Health Questionnaire).

216 ce (Short Physical Performance Battery), and depressive symptoms (Patient Health Questionnaire-8).

217 ional Assessment of Cancer Therapy-General), depressive symptoms (Patient Health Questionnaire-9), an

218 A/Cr, over and above the effects of fatigue, depressive symptoms, physical activity, and psychomotor

219 DL disability (PR, 3.22; 95% CI, 1.72-6.06), depressive symptoms (PR, 11.31; 95% CI, 4.02-31.82), les

220 Depressive symptoms predicted hyperconnectivity in a net

221 Higher maternal depressive symptoms prenatally and postpartum are associ

222 Results: Depression or depressive symptom prevalence data were extracted from 1

223 Depressive symptom prevalence remained relatively consta

224 idence to suggest that a greater severity of depressive symptoms prior to treatment was associated wi

225 In analyses stratified according to baseline depressive symptoms, PSE exerted a preventive effect amo

226 treat and the completer groups) and insight, depressive symptoms, psychosocial functioning, and quali

227 ody dysmorphic disorder severity or insight, depressive symptoms, psychosocial functioning, or qualit

228 eatment, with the 16-item Quick Inventory of Depressive Symptoms (QIDS) serving as the primary effica

229 r and dropout rates; positive, negative, and depressive symptoms; quality of life; functioning; and m

230 relations were found between neuroticism and depressive symptoms (r g = 0.82, standard error (s.e.) =

231 relations were found between neuroticism and depressive symptoms (r g = 0.82, standard error (s.e.) =

232 DR was independently associated with greater depressive symptoms (regression coefficient [beta] = 0.6

233 ence score was significantly associated with depressive symptoms (regression coefficient a = -0.21; P

234 The two loci associated with depressive symptoms replicate in an independent depressi

235 The SNP association was also replicated in a depressive symptom sample that shares some individuals w

236 t significant improvement in clinician-rated depressive symptom score (standardised mean differences

237 rimary outcome was change in clinician-rated depressive symptom score; secondary outcomes were clinic

238 on coefficient a = -0.21; P < .001), and the depressive symptoms score (c = 0.637; P < .001) was sign

239 first-onset depressive disorder and greater depressive symptom scores 18 months later.

240 Lifetime major depressive disorder and depressive symptom scores were used as the outcome measu

241 The primary outcome was improvement in depressive symptom severity from baseline to 12 weeks de

242 roup and showed significant correlation with depressive symptom severity in the OCD group.

243 regression analyses controlling for baseline depressive symptom severity revealed a hazard ratio of 0

244 fer as a function of depression diagnosis or depressive symptom severity.

245 ignificantly more effective than controls on depressive symptoms severity (beta = -0.21; Hedges g = 0

246 00-1960 commonly described 18 characteristic depressive symptoms/signs that substantially but incompl

247 mptoms (including mood and sexual function), depressive symptoms, sleep impairment and poorer PD-rela

248 tion and tract-level poverty), psychosocial (depressive symptoms), socioeconomic (eg, personal and pa

249 appeared more efficacious than controls for depressive symptoms (standardized mean difference: -0.25

250 ntervals, adjusting for demographic factors, depressive symptoms, stress, smoking, alcohol, physical

251 d slightly better mood and lower severity of depressive symptoms than those who received placebo.

252 s in the past year had a greater decrease in depressive symptoms than those without contact (adjusted

253 Food allergy was also associated with depressive symptoms that persisted from adolescence to y

254 antly associated with a broad phenotype from depressive symptoms to major depressive disorder.

255 We examined the association between depressive symptom trajectories and dementia incidence u

256 The following 3 depressive symptom trajectories were identified: consist

257 mal trajectory, having a high and increasing depressive symptom trajectory was associated with signif

258 mary study group, (3) reported depression or depressive symptoms using a validated instrument, and (4

259 association between maternal and adolescent depressive symptoms (Wald test p=0.435 in the GUI cohort

260 1 (SE = 0.02), the SNP-based heritability of depressive symptoms was 0.04 (SE = 0.01), and their gene

261 all pooled crude prevalence of depression or depressive symptoms was 27.2% (37933/122356 individuals;

262 The hazard ratio for depressive symptoms was 3.38 (95% confidence interval (C

263 ntensity of symptoms, the Quick Inventory of Depressive Symptoms was administered bimonthly, and rate

264 Change in depressive symptoms was assessed by calculating the diff

265 s, a 1 SD (three-point) increase in paternal depressive symptoms was associated with an increase of 0

266 Prevalence of moderate/severe depressive symptoms was calculated.

267 A high level of depressive symptoms was defined as a score of 16 or high

268 Prevalence of moderate/severe depressive symptoms was lowest in patients with no clini

269 A significant reduction in depressive symptoms was observed following ketamine admi

270 The prevalence of depressive symptoms was similar in patients with LB comp

271 een loneliness, neuroticism, and a scale of 'depressive symptoms.' We also identified weaker evidence

272 Trajectories of depressive symptoms were assessed from baseline to year

273 sing a monetary guessing task, their current depressive symptoms were assessed using a self-report qu

274 Depressive symptoms were assessed using the Beck Depress

275 Depressive symptoms were assessed with standard assessme

276 s evidence that anxiety, chronic stress, and depressive symptoms were associated with increased risk

277 Higher levels of depressive symptoms were associated with online and soci

278 Depressive symptoms were associated with shorter surviva

279 gnificant posttraumatic stress, anxiety, and depressive symptoms were high and comparable between pat

280 Depressive symptoms were interdependent between patients

281 als of chronic inflammatory conditions where depressive symptoms were measured as a secondary outcome

282 Parental depressive symptoms were measured with the Centre for Ep

283 Adolescent depressive symptoms were measured with the Short Mood an

284 Depressive symptoms were observed in 19.1% before treatm

285 Decreased depressive symptoms were observed in all 19 patients at

286 hose informal caregiver had higher levels of depressive symptoms were significantly more likely to re

287 ty of alcohol abuse, craving, and anxiety or depressive symptoms) were significant after correction f

288 ractice, namely, HRQOL, IADL disability, and depressive symptoms, were significant correlates of frai

289 tically ill patients reported high levels of depressive symptoms, which commonly persisted up to 1 ye

290 itiated ART, the hazard ratio for women with depressive symptoms who had initiated ART was 3.60 (95%

291 Using a reference category of women without depressive symptoms who had initiated ART, the hazard ra

292 Among women reporting depressive symptoms who had not started ART, the hazard

293 For women without depressive symptoms who had not started ART, the hazard

294 We detected significant association of depressive symptoms with a gene NKPD1 (p = 3.7 x 10(-08)

295 d between- and within-person associations of depressive symptoms with LTL and mtDNAcn in a large comm

296 a long-term, between-person relationship of depressive symptoms with LTL, rather than a dynamic and

297 cused on either major depressive disorder or depressive symptoms with mostly negative findings.

298 Significant association of depressive symptoms with NKPD1 was also observed (n = 16

299 of ketamine were repeatedly shown to improve depressive symptoms within 24 h after infusion and this

300 rivation (SD) therapies, dramatically reduce depressive symptoms within 24 hours in a subset of major

301 Depressive symptoms (years 15, 20, 25) were assessed wit